Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676663 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00676663: Completed Phase 2 study, sponsored by Syndax Pharmaceuticals.
NCT00676663 is a Phase 2 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00676663, a Phase 2 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
Primary Outcome
PFS is defined as the number of months from the date of randomization to the earlier of progressive disease (PD) or death due to any cause.
Interventions
- DRUG Placebo
- DRUG exemestane
- DRUG entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-06-13 |
| Est. Completion | 2012-11-26 |
| Phase | Phase 2 |
What the finished NCT00676663 record still lists
NCT00676663 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00676663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00676663 about?
NCT00676663 is a clinical study titled "Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer". The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
What is the current status of trial NCT00676663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-06-13. Estimated completion is 2012-11-26.
What interventions are being tested in trial NCT00676663?
The interventions under investigation include: Placebo (DRUG), exemestane (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT00676663?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00676663's enrollment target sits among peer trials
130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI